



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
Washington, D.C. 20231  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/853,544	05/10/2001	Miguel S. Barbosa	10624-051	7460

20583 7590 10/02/2002

PENNIE AND EDMONDS  
1155 AVENUE OF THE AMERICAS  
NEW YORK, NY 100362711

EXAMINER
----------

PAK, MICHAEL D.

ART UNIT	PAPER NUMBER
----------	--------------

1646

DATE MAILED: 10/02/2002

9

Please find below and/or attached an Office communication concerning this application or proceeding.

# Office Action Summary

Application No.

09/853,544

Applicant(s)

BARBOSA ET AL.

Examiner

Janet L. Andres

Art Unit

1646

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

## Status

- 1) ☐ Responsive to communication(s) filed on \_\_\_\_.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

## Disposition of Claims

- 4) ☒ Claim(s) 1-25 is/are pending in the application.
- 4a) Of the above claim(s) \_\_\_\_ is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) \_\_\_\_ is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_ is/are objected to.
- 8) ☒ Claim(s) 1-25 are subject to restriction and/or election requirement.

## Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.  
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

## Priority under 35 U.S.C. §§ 119 and 120

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a) ☐ All b) ☐ Some \* c) ☐ None of:  
1. ☐ Certified copies of the priority documents have been received.  
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_.  
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  
\* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

## Attachment(s)

- 1) ☐ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_.
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☐ Information Disclosure Statement(s) (PTO-1449) Paper No(s) \_\_\_\_ 6) ☐ Other: \_\_\_\_\_

## DETAILED ACTION

### *Election/Restrictions*

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-12, drawn to methods of evaluating cardiovascular agents, classified in class 435, subclass 7.21.
- II. Claims 13-17, drawn to methods for identifying estrogen receptor modulators, classified in class 435, subclass 7.21.
- III. Claim 18, drawn to a method of inhibiting cardiovascular disease, classified in class 514, subclass 2.
- IV. Claim 19, drawn to a method of inhibiting the development of breast cancer, classified in class 514, subclass 2.
- V. Claim 20, drawn to a method of inhibiting osteoporosis, classified in class 514, subclass 2.
- VI. Claims 21-25, drawn to the nucleic acid SEQ ID NO: 56, classified in class 435, subclass 69.1.
- VII. Claims 21-25, drawn to the nucleic acid SEQ ID NO: 57, classified in class 435, subclass 69.1.
- VIII. Claims 21-25, drawn to the nucleic acid SEQ ID NO: 58, classified in class 435, subclass 69.1.
- IX. Claims 21-25, drawn to the nucleic acid SEQ ID NO: 59, classified in class 435, subclass 69.1.

Art Unit: 1646

- X. Claims 21-25, drawn to the nucleic acid SEQ ID NO: 60, classified in class 435, subclass 69.1.
- XI. Claims 21-25, drawn to the nucleic acid SEQ ID NO: 61, classified in class 435, subclass 69.1.
- XII. Claims 21-25, drawn to the nucleic acid SEQ ID NO: 62, classified in class 435, subclass 69.1.
- XIII. Claims 21-25, drawn to the nucleic acid SEQ ID NO: 63, classified in class 435, subclass 69.1.
- XIV. Claims 21-25, drawn to the nucleic acid SEQ ID NO: 64, classified in class 435, subclass 69.1.
- XV. Claims 21-25, drawn to the nucleic acid SEQ ID NO: 65, classified in class 435, subclass 69.1.
- XVI. Claims 21-25, drawn to the nucleic acid SEQ ID NO: 66, classified in class 435, subclass 69.1.
- XVII. Claims 21-25, drawn to the nucleic acid SEQ ID NO: 67, classified in class 435, subclass 69.1.
- XVIII. Claims 21-25, drawn to the nucleic acid SEQ ID NO: 68, classified in class 435, subclass 69.1.
- XIX. Claims 21-25, drawn to the nucleic acid SEQ ID NO: 69, classified in class 435, subclass 69.1.
- XX. Claims 21-25, drawn to the nucleic acid SEQ ID NO: 70, classified in class 435, subclass 69.1.

Art Unit: 1646

XXI. Claims 21-25, drawn to the nucleic acid SEQ ID NO: 71, classified in class 435, subclass 69.1.

XXII. Claims 21-25, drawn to the nucleic acid SEQ ID NO: 72, classified in class 435, subclass 69.1.

XXIII. Claims 21-25, drawn to the nucleic acid SEQ ID NO: 73, classified in class 435, subclass 69.1.

XXIV. Claims 21-25, drawn to the nucleic acid SEQ ID NO: 74, classified in class 435, subclass 69.1.

XXV. Claims 21-25, drawn to the nucleic acid SEQ ID NO: 75, classified in class 435, subclass 69.1.

Claims appear in more than one group because they encompass more than one invention.

The inventions are distinct, each from the other because of the following reasons:

The methods of Invention I are distinct from the methods of Invention II because they have different method steps, require different reagent steps, and can identify different agents.

The methods of Invention I are not related to the methods of Inventions III-V because they have different method steps, require different reagents, and have different goals and outcome measures.

The methods of Invention I are distinct from the nucleic acids of Inventions VI-XXV because the nucleic acids have other uses, such as the generation of protein.

Art Unit: 1646

The methods of Invention II are not related to the methods of Inventions III-V because they have different method steps, require different reagents, and have different goals and outcome measures.

The methods of Invention II are distinct from the nucleic acids of Inventions VI-XXV because the nucleic acids have other uses, such as the generation of protein.

The methods of Invention III are distinct from those of Inventions IV because they have different goals and different outcome measures.

The methods of Invention III are distinct from those of Invention V because they have different goals and different outcome measures.

The methods of Invention III are not related to the nucleic acids of Inventions VI-XXV.

The nucleic acids cannot be use in the methods.

The methods of Invention IV are distinct from those of Invention V because they have different goals and different outcome measures.

The methods of Invention IV are not related to the nucleic acids of Inventions VI-XXV.

The nucleic acids cannot be use in the methods.

The methods of Invention V are not related to the nucleic acids of Inventions VI-XXV.

The nucleic acids cannot be use in the methods.

The nucleic acids of Inventions VI-XXV are distinct, each from the other, because each individual sequence is a structurally and functionally distinct entity with different physical and biological characteristics from each other sequence.

Art Unit: 1646

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, restriction for examination purposes as indicated is proper.

Because these inventions are distinct for the reasons given above and the searches required for the different groups are different, restriction for examination purposes as indicated is proper.

This application contains claims directed to the following patentably distinct species of the claimed invention: For Groups I and II, the species are

The nucleic acids represented by SEQ ID Nos 1-75.

Each of these is a structurally and functionally distinct entity; a search of one would not reveal art relevant to another. Further, one would not render another obvious.

If either Invention I or Invention II is elected, Applicant is required under 35 U.S.C. 121 to elect a single disclosed species for prosecution on the merits to which the claims shall be restricted if no generic claim is finally held to be allowable.

Applicant is advised that a reply to this requirement must include an identification of the species that is elected consonant with this requirement, and a listing of all claims readable thereon, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered nonresponsive unless accompanied by an election.

Upon the allowance of a generic claim, applicant will be entitled to consideration of claims to additional species which are written in dependent form or otherwise include all the

Art Unit: 1646

limitations of an allowed generic claim as provided by 37 CFR 1.141. If claims are added after the election, applicant must indicate which are readable upon the elected species. MPEP § 809.02(a).

Should applicant traverse on the ground that the species are not patentably distinct, applicant should submit evidence or identify such evidence now of record showing the species to be obvious variants or clearly admit on the record that this is the case. In either instance, if the examiner finds one of the inventions unpatentable over the prior art, the evidence or admission may be used in a rejection under 35 U.S.C. 103(a) of the other invention.

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Janet Andres, Ph.D., whose telephone number is (703) 305-0557. The examiner can normally be reached on Monday through Friday from 8:00 am to 5:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Yvonne Eyler, Ph.D., can be reached at (703) 308-6564. The fax phone number for this group is (703) 872-9306 or (703) 872-9307 for after final communications.

Communications via internet mail regarding this application, other than those under U.S.C. 132 or which otherwise require a signature, may be used by the applicant and should be addressed to [yvonne.eyler@uspto.gov](mailto:yvonne.eyler@uspto.gov).

All Internet email communications will be made of record in the application file. PTO employees do not engage in Internet communications where there exists a possibility that sensitive information could be identified or exchanged unless the record includes a properly signed express waiver of the confidentiality requirements of 35 U.S.C. 122. This is more clearly




Art Unit: 1646

set forth in the Interim Internet Usage Policy published in the Official Gazette of the Patent and Trademark Office on February 25, 1997 at 1195 OG 89.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Group receptionist whose telephone number is (703) 308-0196.

Janet Andres, Ph.D.  
October 1, 2002

  
YVONNE EYLER, PH.D  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600